Workflow
盐酸纳洛酮注射液
icon
Search documents
中关村股价微涨0.36% 上半年扣非净利润同比增长36.34%
Jin Rong Jie· 2025-08-26 18:01
风险提示:以上内容仅供参考,不构成投资建议。市场有风险,投资需谨慎。 根据公司最新披露的2025年半年度报告,上半年实现营业收入12.39亿元,归属于上市公司股东的扣除 非经常性损益的净利润3685.49万元,同比增长36.34%。其中,战略产品"盐酸羟考酮注射液"营业收入 同比增长逾90%,"盐酸纳洛酮注射液"中选第十批国家组织药品集中采购。在研发方面,公司多个药品 上市许可申请获得国家药监局受理。 8月26日,中关村主力资金净流入399.25万元,近五个交易日累计净流入1691.89万元。 截至2025年8月26日15时,中关村最新股价为5.63元,较前一交易日上涨0.36%。当日开盘价为5.58元, 最高触及5.67元,最低下探5.55元,成交量为20.24万手,成交金额达1.14亿元。 中关村所属化学制药板块,公司主营业务涵盖生物医药及健康品、商砼、养老医疗三大领域。作为北京 地区医药企业,公司拥有盐酸贝尼地平片、盐酸羟考酮注射液等核心产品,并布局创新药研发。 ...
中关村:上半年扣非净利润同比增长36.34%
Zhong Zheng Wang· 2025-08-26 14:01
中证报中证网讯(王珞)8月26日晚间,中关村(000931)(000931)发布2025年半年度报告。报告期 内,公司实现营业收入12.39亿元,同比下降2.71%;实现净利润3881万元,同比增长6.65%;扣非净利 润3685万元,同比增长36.34%。 此外,公司健康品业务持续推进"华素愈创""华素清清"等产品的终端推广和营销升级工作。报告期内, 先后参加北京国际口腔展、华南国际口腔展、东北国际口腔展、江西省口腔展会四大口腔展会。通过与 连锁药店战略合作和区域代理商合作等手段,推进产品市场覆盖范围,扩大业务规模,提升品牌知名 度。报告期内,中关村已与多家口腔诊所达成合作意向,后续公司将继续推进相关工作的进一步开展。 北京华素OTC渠道销售方面,在产品策划端,公司通过整合多元宣传手段,精准锚定目标受众,构建品 牌传播矩阵,提升品牌知名度。在销售端,紧密携手头部连锁企业,高效推进铺货进程。同时,高频次 开展市场推广活动,全方位赋能终端动销。报告期内,"华素片""盐酸苯环壬酯片(商品名:飞赛 乐)"等主要产品均较好地完成半年度销售任务;其中,"华素片"与"风度片"在乌镇健康大会中斩获"最 受药店欢迎的明星单品 ...
聚焦医药大健康主业 中关村上半年扣非净利润同比增长36.34%
本报讯 (记者向炎涛)8月26日晚,北京中关村科技发展(控股)股份有限公司(以下简称"中关村") 发布2025年半年度报告。上半年,公司实现营业收入12.39亿元,较上年同期基本持平;实现归属于上 市公司股东的净利润3880.89万元,同比增长6.65%;实现归属于上市公司股东的扣除非经常性损益的净 利润3685.49万元,同比增长36.34%。 报告期内,公司继续聚焦主业,推动精细化管理迈向更高阶段。同时,公司坚持内外结合,充分利用外 部资源,完善、丰富产品线,保持投入,夯实未来发展基础。 生物医药及健康品业务方面,公司药品生产和研发工作取得积极进展。报告期内,公司旗下北京华素收 到北京市药品监督管理局下发的《药品生产许可证》,生产范围增加原料药联苯苄唑,有利于公司优化 生产结构,丰富公司产品布局,满足市场需求。 药品销售工作方面,北京华素主要产品富马酸比索洛尔片(商品名:博苏)销量与上年同期基本持平, 核心产品盐酸贝尼地平片(注册商标:元治®)较上年同期继续保持增长;同时,战略产品"盐酸羟考 酮注射液"营业收入较上年同期增长逾90%。报告期内,"盐酸纳洛酮注射液"成功中选第十批国家组织 药品集中采购。 作 ...
中关村:关于下属公司山东华素琥珀酸美托洛尔原料药获批上市的公告
Zheng Quan Ri Bao· 2025-08-22 15:41
证券日报网讯 8月22日晚间,中关村发布公告称,公司于2024年3月披露《关于下属公司北京华素盐酸 纳洛酮注射液一致性评价申报和山东华素琥珀酸美托洛尔原料药申报收到国家药监局的公告》。近日, 公司下属公司山东华素制药有限公司(简称"山东华素")"琥珀酸美托洛尔原料药"于近日通过国家药品 监督管理局药品审评中心技术审评,并获得国家药品监督管理局核准签发的《化学原料药上市申请批准 通知书》。 (文章来源:证券日报) ...
持续聚焦优势细分领域 莱美药业上半年实现营收3.77亿元
Group 1 - The company is building a three-dimensional research and innovation system focusing on short, medium, and long-term goals, actively introducing quality projects and innovative technologies in the short to medium term [1] - The technology center continues to conduct research on new drug imitation and innovation, enhancing the company's product portfolio and competitiveness in specific fields [1] - The company is advancing the development of innovative technologies and products such as nano carbon iron in the long term, and is promoting the independent research and development of cell immunotherapy and personalized innovative medical technologies by its affiliate [1] Group 2 - In the reporting period, the company obtained approvals or supplementary application approvals for various products, including Clindamycin Phosphate Injection and Naloxone Hydrochloride Injection, and passed consistency evaluations [1] - The company’s product Esomeprazole Magnesium Enteric-coated Capsules and others were selected for provincial centralized procurement projects, enhancing market share [1] - Laimei Pharmaceutical reported a revenue of 377 million yuan for the first half of 2025, focusing on consolidating the leading position of its flagship product, Kanalin, in its niche market [2]
中恒集团:以可持续发展为轴 卷动社会价值共创新生态
Core Insights - Zhongheng Group has released its 15th Social Responsibility Report, highlighting its practices in rural revitalization, green low-carbon transformation, and ensuring public welfare, receiving multiple honors including recognition in the ESG Pioneer 100 Index and as an excellent practice case for sustainable development in 2024 [1] Group 1: Green Development and Low-Carbon Transformation - The company is committed to green development, aligning with the national "dual carbon" goals, and has invested in energy conservation, emission reduction, clean production, and renewable energy utilization [1] - Zhongheng promotes green pest control and wild-simulated planting techniques, and is establishing a rescue base for the national second-level protected plant, promoting a green ecological circle for traditional Chinese medicine [1] - The company extends its environmental protection philosophy through activities like World Environment Day and tree planting [1] Group 2: Social Responsibility and Health Care - Zhongheng actively responds to national policies, with multiple products renewing contracts or winning bids in national and provincial centralized procurement, enhancing the accessibility of clinical medications and reducing patient burdens [1] - The company explores a "industry + technology + public welfare" model for rural revitalization, supporting the construction of traditional Chinese medicine material bases to increase farmers' income [1] - Zhongheng integrates intangible cultural heritage techniques with modern production technology to develop new products like sugar-free Liubao tea and black bean milk [1] - The company engages in volunteer services such as the Zhongheng Scholarship, Mother's Smile Initiative, and the Elderly and Children Care Project, continuously delivering warmth to society [1] Group 3: Corporate Governance and Development - Zhongheng focuses on modernizing its governance system, continuously improving its governance structure and establishing a long-term shareholder return mechanism [2] - Since its listing, the company has distributed a total of 2.941 billion yuan in dividends and repurchased nearly 173 million shares, demonstrating confidence in its corporate value [2] - In 2024, Zhongheng plans to establish three new provincial-level research platforms and has been approved for two Guangxi Natural Science Fund projects [2] - The company is advancing the development of innovative traditional Chinese medicine products and has received approvals for multiple drug varieties, solidifying its position in the industry [2] - Zhongheng aims to maintain a pragmatic approach, collaborating with partners to contribute to comprehensive reform and the modernization of China [2]
中 关 村(000931) - 2025年5月12日投资者关系活动记录表
2025-05-12 09:08
Group 1: Company Strategy and Resource Allocation - The company focuses on the pharmaceutical health sector and plans to divest non-pharmaceutical assets to optimize its resource allocation over the next 3 to 5 years [2] - The company will carefully consider market trends and the status of existing assets before making decisions on asset optimization [2] Group 2: Product Performance and Market Trends - The core product, Benidipine Hydrochloride Tablets (trademark: Yuanzhi®), saw a nearly 29% increase in revenue in 2024 compared to the previous year [2] - The market share of Yuanzhi reached 55.57% in 2024, driven by an aging population and increasing hypertension cases [3] Group 3: Sales and Marketing Strategies - The company implemented a "three-full strategy" to expand its market presence and mitigate the impact of potential centralized procurement [2] - Sales expenses increased to 44.22% in Q1 2025 from 35.75% in 2024, attributed to heightened marketing efforts to ensure strong performance [7] Group 4: Future Growth and Product Development - The company anticipates a sales revenue increase of over 100% for Oxycodone Injection in 2025, supported by expanding usage in various medical fields [5] - The company is developing new products, including Methylphenidate Hydrochloride sustained-release tablets, with significant market potential in ADHD treatment [6] Group 5: Financial Projections - The company projects a revenue of 2.943 billion yuan and a net profit of 89 million yuan for 2025 [10] - In Q1 2025, the company achieved a revenue of 616 million yuan, a 1.63% increase year-on-year, and a net profit of 15.76 million yuan, up 35.47% from the previous year [10] Group 6: Digital Transformation and E-commerce - The company is advancing digital initiatives, including the establishment of digital workshops and exploring online sales channels [7] - The health product segment is focusing on expanding its product range and enhancing e-commerce operations to meet diverse consumer needs [8]
津药药业股份有限公司2025年第一季度报告
Core Viewpoint - The company has reported its first-quarter financial results for 2025, highlighting significant developments in product approvals and strategic initiatives aimed at enhancing operational efficiency and shareholder returns [12][28]. Financial Data - The company achieved a revenue of 3.215 billion yuan and a net profit attributable to shareholders of 133 million yuan in 2024 [12]. - The company plans to distribute a cash dividend of 0.98 yuan per 10 shares for the 2024 fiscal year, totaling approximately 107 million yuan, maintaining a cash dividend ratio of 80.18% [15]. Product Approvals and Market Expansion - The company received approval for the active pharmaceutical ingredient (API) Fumarate Formoterol and the inhalation solution from the National Medical Products Administration, which is expected to enhance its market presence [5]. - The company’s Dexamethasone Sodium Phosphate API has been approved for sale in Brazil, which will aid in expanding its international market footprint [5]. - The company obtained a production license for special dietary foods covering 26 amino acids, enhancing its operational capabilities [5]. Research and Development - In 2024, the company invested 248 million yuan in R&D, representing 7.7% of its main business revenue, and achieved significant milestones in drug approvals [16]. - The company plans to focus on six key areas, including ophthalmology and dermatology, to enhance its product pipeline and market competitiveness [17]. Compliance and Governance - The company is committed to enhancing its compliance management systems and has implemented various measures to improve operational efficiency and risk management [18][22]. - The company has revised its governance documents to align with regulatory requirements and improve its response to public sentiment [22]. Investor Relations - The company emphasizes the importance of information disclosure and has actively engaged with investors through various channels, including regular reports and investor education initiatives [20][21]. - The company has received a B-level rating for information disclosure from the Shanghai Stock Exchange, reflecting its commitment to transparency [20].
北京中关村科技发展(控股)股份有限公司关于盐酸纳洛酮注射液中选第十批全国药品集中采购的公告
Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has been selected in the 10th batch of national drug centralized procurement for its product, Naloxone Hydrochloride Injection, which is expected to positively impact the company's future performance and market presence [1][2]. Group 1: Product Information - Product Name: Naloxone Hydrochloride Injection - Dosage Form: Injection - Specification: 1ml:1mg - Packaging: 10 vials/box - Indications: Used for reversing respiratory depression caused by opioid drugs, treating opioid overdose, and diagnosing acute opioid overdose [1][2]. Group 2: Procurement Details - Selected Price: 0.99 yuan per vial - Supply Provinces: Inner Mongolia, Liaoning, Jilin, Hunan, Qinghai - Backup Supply Provinces: Beijing, Tianjin, Zhejiang, Anhui, Jiangxi - Selected Company: Beijing Huasu Pharmaceutical Co., Ltd. [2]. Group 3: Impact on the Company - The selected product is classified as a Class A product under the national medical insurance scheme, with a procurement period from the selection date until December 31, 2027 - Medical institutions will prioritize the use of selected products, which is expected to enhance the company's sales channels and market share for Naloxone Hydrochloride Injection - The successful implementation of procurement contracts will contribute positively to the company's operational performance and long-term development [2].
津药药业股份有限公司关于子公司获得药品注册证书的公告
Group 1 - The company announced that its subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd., has received the drug registration certificate for Naloxone Hydrochloride Injection from the National Medical Products Administration [1] - The drug is an opioid receptor antagonist, and the company has invested approximately 4.2 million yuan in the research and development of this product [1][2] - The domestic sales of Naloxone Hydrochloride Injection were 413 million yuan in 2022 and are projected to be 535 million yuan in 2023, indicating a growth in market demand [2] Group 2 - The approval of the drug registration certificate enhances the company's formulation product portfolio and is expected to positively impact the company's performance in the domestic formulation market [3] - However, the sales timeline, scale, and future expansion of the drug in the domestic market remain uncertain due to competitive market conditions [3]